Eli Lilly Says Once-Weekly Insulin Meets Key Goal in Two Studies
By Colin Kellaher
Eli Lilly on Thursday said a pair of late-stage studies of its proposed once-weekly insulin efsitora alfa met their primary endpoints.
The Indianapolis drugmaker said efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally in the Phase 3 studies in adults with type 2 diabetes using insulin for the first time and those who require multiple daily injections.
Eli Lilly said efsitora was safe and well-tolerated in both studies, adding that it expects topline readouts from three additional trials later this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 16, 2024 07:34 ET (11:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks